Tenax Therapeutics Q4 EPS $(11.84) Misses $(8.14) Estimate
Portfolio Pulse from dijoy@benzinga.com
Tenax Therapeutics reported Q4 EPS losses of $(11.84), missing the consensus estimate of $(8.14) by 45.45%. However, this represents an 83.74% improvement over the previous year's losses of $(72.80) per share.

March 28, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tenax Therapeutics reported a larger-than-expected Q4 EPS loss of $(11.84), missing estimates by 45.45%, but showed significant improvement from last year.
The reported EPS loss was significantly worse than the analyst consensus, which typically leads to negative investor sentiment in the short term. However, the improvement from the previous year's loss indicates some progress, which might mitigate the negative impact slightly.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100